Welcome back to Healthy Innovations! 👋

Chronic pain affects more people than heart disease, diabetes, and cancer combined – yet for most of medical history, medicine may have been treated it by looking in the wrong place.

This week we're exploring what happens when researchers move beyond the injury and start examining the brain that's interpreting it. The clinical evidence is finally maturing, and for patients who've been told there's nothing left to try, the implications are significant.

Let's dive in!

Cassandra H. spent decades on her feet. A clinical pharmacist at a busy hospital, she played volleyball and basketball as a young woman and kept bowling and golfing well into her sixties. Then a routine procedure went wrong, and she developed complex regional pain syndrome (CRPS) in her left foot.

The pain was so severe, so constant, that she could no longer bear weight. Normal daily life – gone.

At the Shirley Ryan AbilityLab in Chicago – consistently ranked the number one rehabilitation hospital in the US by U.S. News & World Report – her treatment team did something unusual. Instead of focusing only on the foot, they focused on the brain.

She worked on an anti-gravity treadmill to rebuild movement confidence, and did mirror therapy – watching her unaffected right foot while her brain slowly re-mapped the left. And along the way she encountered a counterintuitive truth that pain science researchers have spent decades trying to get into clinical practice: her brain had learned to produce pain – and it could, with the right help, learn to produce less of it.

"I learned that my brain was trying to protect my foot through pain," Cassandra told Shirley Ryan's team, "but I actually needed to reprogram it to start reducing my pain."

Chronic pain – lasting three months or longer – often persists long after any original tissue damage has resolved, or in the complete absence of detectable injury. Scans look normal, blood work is clear. And yet the pain is entirely real and severely disabling.

The explanation – in many cases – lies in a process called central sensitization: a state in which the nervous system itself becomes hyperexcitable, amplifying pain signals and generating them even when no tissue threat exists. Neurons in the spinal cord and brain fire more easily, for longer, in response to lower thresholds. A 2025 review in BJA Education describes it as "increased responsiveness of nociceptive neurones in the central nervous system to their normal or subthreshold afferent input." The alarm system is stuck on. The original danger has passed, but the brain is still treating ordinary sensations as threats.

Central sensitization is not present in every chronic pain condition – pain is always an interaction of peripheral input and central processing, not a simple either/or. But where altered central processing is driving the experience, approaches aimed solely at the tissue often fall short. Surgery, injections, structural manipulation: these address what the clinician can see on a scan. They do not address how the nervous system has reorganized itself around the experience of pain.

The good news: the nervous system can reorganize again. That's neuroplasticity. And a new generation of clinical interventions is learning to use it deliberately.

One of the most established brain-targeted interventions is graded motor imagery (GMI) – a three-phase protocol developed at the University of South Australia.

It doesn't start with movement. It starts with perception.

The protocol moves through three stages:

The logic: the brain's representation of the body has become distorted. GMI rebuilds it, step by step, before asking the body to actually move.

A 2024 systematic review and meta-analysis in Pain Practice found that motor imagery significantly reduced pain intensity and improved function in CRPS patients across six randomized controlled trials. A separate 2024 review in Biomedicines reported that, pooled across the small trials included, GMI and mirror therapy reduced scores on the Neuropathic Pain Scale by an average of 20 points, with functional improvements also seen – though the authors note the limitations of small sample sizes and mixed designs.

The effects go beyond what minimal intervention alone would predict, though the precise mechanisms – and the role of expectation and therapeutic context – remain actively debated in the literature.

If GMI works partly through visual feedback, virtual reality is a natural extension – and the clinical evidence is catching up with the technology.

A 2024 randomized controlled trial from the Icahn School of Medicine at Mount Sinai found that immersive VR environments produced significant pain reductions and quality-of-life improvements in patients with chronic neuropathic pain after spinal cord injury. A 2025 scoping review in the Journal of Medical Internet Research confirmed that VR-based therapies targeting kinesiophobia – the fear of movement that often entrenches chronic pain – have an emerging evidence base, particularly in musculoskeletal conditions.

The most significant regulatory milestone came from AppliedVR's RelieVRx program, which in 2021 became the first VR-based digital therapeutic to receive FDA De Novo authorization for chronic lower back pain. Developed with pain specialists, the program delivers 56 short sessions of cognitive behavioral therapy and pain neuroscience education through a VR headset at home. A randomized placebo-controlled trial of over 1,000 participants found clinically meaningful reductions in pain intensity and interference across the severity spectrum.

The mechanism extends beyond distraction. At its most effective, VR incorporates graded exposure to feared movements and cognitive reframing of pain – overlapping substantially with the neuroplasticity principles underlying GMI.

In November 2025, The Lancet Rheumatology published three-year follow-up data from the RESTORE trial.

RESTORE was a three-arm randomized controlled trial across 20 primary care physiotherapy clinics in Australia, testing cognitive functional therapy (CFT) against usual care in patients with chronic disabling low back pain. CFT is a highly individualized approach that addresses both the psychological and physical dimensions of pain – helping patients examine and change their relationship to pain, the fear, and the movement patterns reorganized around protecting something that may no longer need protecting.

At three years, CFT produced clinically meaningful reductions in disability and durable – if modest – reductions in pain intensity compared with usual care. The Lancet Rheumatology described it as the first treatment for chronic disabling low back pain with strong evidence of effectiveness lasting more than a year – a claim that reflects how few interventions have shown sustained benefit, rather than an absence of other long-term data. In a field where most approaches fade quickly, that distinction still matters.

For the over 600 million people worldwide affected by low back pain, this is not a silver bullet. What it confirms is that a brain-and-behavior-targeted approach can produce durable change where anatomy-focused treatments have repeatedly failed.

The interventions covered here share a common thread. They ask the brain to update a model of the body that has become miscalibrated. None are standalone cures – they work best as part of multimodal care, alongside appropriate physical rehabilitation and, where needed, pharmacological support. They are not passive. They require patient effort and a willingness to move toward something the nervous system has been flagging as dangerous.

That is both their strength and their current limitation:

The evidence is maturing faster than the infrastructure to deliver it.

For healthcare leaders: the biological case is now well-established. The clinical trials are producing durable results. What has not kept pace is implementation – the reimbursement infrastructure and clinical culture change needed for pain medicine to move from fixing tissues to retraining brains.

Cassandra, for her part, is back on her feet.

🐦 Your immune system might be a compass. Scientists have been trying to explain how homing pigeons navigate for decades. The answer was hiding in a place no one thought to look: the liver.

A study published in Science by researchers at the Max Planck Institute found that iron-rich immune cells in pigeon livers accumulate iron while recycling old red blood cells – and in doing so, acquire magnetic properties that let them sense Earth's magnetic field. Remove those cells, and pigeons fly fine on sunny days. Put them under overcast skies, and all 18 test birds got hopelessly lost, only finding home once the clouds cleared.

The researchers believe the same mechanism may explain navigation in bats and blind mole rats – and wonder whether something similar operates in other animals. Possibly even us.

Thank you for reading the Healthy Innovations newsletter!

Keep an eye out for next week’s issue, where I will highlight the healthcare innovations you need to know about.

Have a great week!

Alison ✨

P.S. If you enjoyed reading the Healthy Innovations newsletter, please subscribe so I know the content is valuable to you!